Your browser is no longer supported. Please, upgrade your browser.
Settings
AKAO Achaogen, Inc. daily Stock Chart
AKAO [NASD]
Achaogen, Inc.
Index- P/E- EPS (ttm)-4.26 Insider Own7.69% Shs Outstand63.88M Perf Week-
Market Cap- Forward P/E- EPS next Y-0.99 Insider Trans- Shs Float50.95M Perf Month-
Income- PEG- EPS next Q-0.52 Inst Own46.66% Short Float14.76% Perf Quarter-
Sales8.73M P/S- EPS this Y65.20% Inst Trans- Short Ratio- Perf Half Y-
Book/sh-0.13 P/B- EPS next Y30.80% ROA- Target Price12.50 Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range- - - Perf YTD-
Dividend- P/FCF- EPS past 5Y- ROI- 52W High- Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low- ATR-
Employees42 Current Ratio- Sales Q/Q8.30% Oper. Margin- RSI (14)- Volatility- -
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume- Prev Close-
ShortableNo LT Debt/Eq- Earnings- Payout- Avg Volume- Price-
Recom2.50 SMA20- SMA50- SMA200- Volume0 Change-
Jun-06-19 06:46PM  Achaogen, Inc. Announces Results of Auction for Substantially All Company Assets GlobeNewswire
Apr-26-19 10:30AM  Achaogen (AKAO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks
Apr-16-19 07:17PM  Achaogen (AKAO) Files for Bankruptcy, Shares Plunge 65% Zacks
Apr-15-19 12:33PM  Achaogen's Bankruptcy Filing, Proposed Sale: What You Need to Know Benzinga
07:48AM  Achaogen Plans for Near-Term Sale Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Code GlobeNewswire
Apr-10-19 01:06PM  Edited Transcript of AKAO earnings conference call or presentation 28-Mar-19 8:30pm GMT Thomson Reuters StreetEvents
Apr-09-19 09:00AM  Achaogen (AKAO) Upgraded to Buy: Here's Why Zacks
Apr-01-19 05:48PM  Achaogen Inc (AKAO) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
Mar-28-19 04:24PM  Achaogen: 4Q Earnings Snapshot Associated Press
04:01PM  Achaogen Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update GlobeNewswire
Achaogen, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial agents for multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California. On April 15, 2019, Achaogen, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DUGGAN ROBERT W10% OwnerMar 20Sale0.5350,00026,5005,555,414Mar 20 05:24 PM
DUGGAN ROBERT W10% OwnerMar 19Sale0.53956,009506,6855,605,414Mar 20 05:24 PM
DUGGAN ROBERT W10% OwnerMar 18Sale0.56271,879152,2526,561,423Mar 20 05:24 PM
DUGGAN ROBERT W10% OwnerMar 13Sale0.591,199,930707,9596,833,302Mar 13 05:31 PM
DUGGAN ROBERT W10% OwnerMar 12Sale0.61633,975386,7258,033,232Mar 13 05:31 PM
DUGGAN ROBERT W10% OwnerMar 11Sale0.63520,102327,6648,667,207Mar 13 05:31 PM
Bhatt ElizabethChief Operating OfficerFeb 21Sale0.89971864238,155Feb 25 08:45 PM
Dorling JanetChief Commercial OfficerFeb 21Sale0.891,063946284,738Feb 25 08:44 PM
Sarpangal ZerynChief Financial OfficerFeb 21Sale0.891,3881,235242,546Feb 25 08:43 PM
LOEB GARYSee RemarksFeb 21Sale0.89791704239,673Feb 25 08:42 PM
Wise BlakeChief Executive OfficerFeb 21Sale0.893,7713,356505,650Feb 25 08:41 PM
Dorling JanetChief Commercial OfficerFeb 05Sale1.358181,104285,801Feb 07 08:00 PM
DUGGAN ROBERT W10% OwnerDec 11Buy1.65306,848505,0109,187,309Dec 12 06:23 PM
DUGGAN ROBERT W10% OwnerDec 10Buy1.60436,500697,7898,880,461Dec 12 06:23 PM
DUGGAN ROBERT W10% OwnerDec 07Buy1.4022,43131,3948,443,961Dec 11 05:44 PM
DUGGAN ROBERT W10% OwnerNov 27Buy1.6877,585129,9638,421,530Nov 27 05:22 PM
DUGGAN ROBERT W10% OwnerNov 23Buy1.8980,175151,6438,343,945Nov 27 05:22 PM
DUGGAN ROBERT W10% OwnerNov 20Buy1.93231,495446,9478,263,770Nov 23 01:45 PM
DUGGAN ROBERT W10% OwnerNov 19Buy1.624,6487,5258,032,275Nov 20 04:08 PM